Warren Pharmaceuticals, Inc. is a privately held biotech company that was incorporated in 2001 for the purpose of developing proprietary tissue-protective technologies.
Warren Pharmaceuticals pioneered the discovery of a new therapeutic class of compounds named tissue protective cytokines (TPCs), which are proteins with potent protective effects that diminish and reverse the underlying cellular damage in many diseases and injuries.
Stroke, heart attack, paralysis from spinal cord injury, blindness from retinal damage, and kidney failure share common mechanisms of cellular injury that impair recovery. These indications represent significant patient populations and disease areas with limited therapeutic options, and for which new treatment modalities have the potential to fundamentally alter current medical practice.
Warren Pharmaceuticals’ TPCs suppress the underlying pathology in which the body’s own inflammatory response overreacts to the often minor and local causative insult, and aggressively induces widespread damage to attempt to isolate and eradicate it.
Warren Pharmaceuticals was named in honor of the late Kenneth S. Warren, M.D., physician, scientist, educator, administrator and humanist who was dedicated to improving the health of the rural poor of the world.
Officers & Senior Management
Warren Pharmaceuticals' management team consists of experienced professionals, having served many years in their respective fields of corporate management, preclinical discovery and research, and clinical development.
Anthony Cerami, PhD - Chairman and Chief Executive Officer
Michael Brines, MD, PhD - Chief Scientific Officer
Board of Directors
Anthony Cerami, PhD - Chairman
Michael Brines, MD, PhD
John D. Macomber, MBA
Jesper Zeuthen, M.Sc., D.Sc.
Warren Pharmaceuticals' partnering strategy is based on leveraging its expertise in biotechnology innovation with commercial partners having the resources to develop and market ethical products.
H. Lundbeck A/S
In October 2001, Warren executed a License and Research Agreement with H. Lundbeck A/S (Lundbeck), a publicly traded Danish pharmaceutical company. Lundbeck focuses on the development of therapeutics for the treatment of diseases of the central nervous system. Pursuant to the license agreement, Lundbeck was granted exclusive global rights to develop and market TPCs in the therapeutic areas of the central and peripheral nervous systems, excluding diabetic neuropathies and other conditions which do not have primarily neurological and/or psychiatric symptoms.
In October 2007, Lundbeck announced it had initiated phase I clinical trials on Lu AA24493, a carbamoylated form of human erythropoietin (EPO), in patients suffering from acute cerebral stroke.
Click here to download the press release.
The BankInvest Group
In October 2001, The Danish asset management firm BankInvest Group purchased an equity position in Warren. The BankInvest Group has been an active investor in the biotechnology industry since 1988 and is the leading independent Nordic asset manager of mutual funds, venture capital and discretionary mandates for institutional clients. BioVenture, the venture capital portion of the BankInvest Group, invests exclusively in private companies within the biotechnology sector.
Warren has licensed the worldwide development and commercialization rights to the central and peripheral nervous system indications of its TPCs other than ophthalmic and diabetes to the Danish pharmaceutical company H. Lundbeck A/S.
See the description of our partners, above.
Return to top of page